

**NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS**  
**Request for Coverage of Insured Asthma Inhalers**

**PATIENT INFORMATION**

|                        |                           |                           |                      |
|------------------------|---------------------------|---------------------------|----------------------|
| <b>PATIENT SURNAME</b> | <b>PATIENT GIVEN NAME</b> | <b>HEALTH CARD NUMBER</b> | <b>DATE OF BIRTH</b> |
| <b>PATIENT ADDRESS</b> |                           |                           |                      |

**SECTION 1: REQUESTED INHALER**

**LABA OR LABA/ICS MONOTHERAPY**

|  |           |  |
|--|-----------|--|
| <b>Long Acting Beta2-Agonist (LABA) Monotherapy:</b><br><input type="checkbox"/> Oxeze <input type="checkbox"/> Serevent | <b>OR</b> | <b>Long Acting Beta2-Agonist (LABA)/Inhaled Steroid (ICS) Monotherapy:</b><br><input type="checkbox"/> Aectura <input type="checkbox"/> Advair and generic brands <input type="checkbox"/> Breo Ellipta<br><input type="checkbox"/> Symbicort <input type="checkbox"/> Zenhale |
|--|-----------|--|

**For the treatment of patients who:**

Have moderate to severe asthma **and**

Are compliant with inhaled corticosteroids at optimal doses; (please provide details below) **and**

Require additional symptom control, (e.g., cough, awakening at night, missing activities such as school, work or social activities because of asthma symptoms); **and**

Require increasing amounts of short-acting beta2-agonists, indicative of poor control (please provide details below)

**ICS/LAMA/LABA TRIPLE THERAPY**

Enerzair

**For the treatment of adult patients who:**

Have asthma **and**

Are not adequately controlled with a maintenance combination of a long-acting beta2-agonist (LABA) and a medium or high dose of an inhaled corticosteroid (ICS) (please provide details below) **and**

Experienced one or more asthma exacerbations in the previous 12 months.

**Please note:** Asthma exacerbation is defined as: worsening signs or symptoms of asthma (shortness of breath, cough, wheezing or chest tightness and progressive decrease in lung function) requiring administration of systemic corticosteroids for at least three days, or asthma-related hospitalization.

**SECTION 2: PREVIOUS INHALER THERAPY**

**Please provide details of previous inhaler therapy:**

| Inhaler | Dose | Start Date/ Duration of Therapy | Outcome |
|---------|------|---------------------------------|---------|
|         |      |                                 |         |
|         |      |                                 |         |
|         |      |                                 |         |

**Additional Comments (if applicable):**

  
  

|                                       |                      |       |
|---------------------------------------|----------------------|-------|
| <b>PRESCRIBER NAME &amp; ADDRESS:</b> |                      |       |
| _____                                 | _____                | _____ |
| LICENCE #                             | PRESCRIBER SIGNATURE | DATE  |

**If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026**

**Please Return Form To:** Nova Scotia Pharmacare Programs  
 P.O. Box 500, Halifax, NS B3J 2S1; Fax: (902) 496-4440

